vs
FREQUENCY ELECTRONICS INC（FEIM）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是FREQUENCY ELECTRONICS INC的1.1倍（$19.6M vs $17.1M），FREQUENCY ELECTRONICS INC净利率更高（10.5% vs -177.4%，领先187.9%），FREQUENCY ELECTRONICS INC同比增速更快（8.3% vs -11.5%），FREQUENCY ELECTRONICS INC自由现金流更多（$-1.1M vs $-23.1M），过去两年FREQUENCY ELECTRONICS INC的营收复合增速更高（11.8% vs -12.2%）
超电子控股是一家英国国防与安全企业，曾在伦敦证券交易所上市，是富时250指数成分股之一，后被隶属于安宏资本的科巴姆公司收购。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
FEIM vs LAB — 直观对比
营收规模更大
LAB
是对方的1.1倍
$17.1M
营收增速更快
FEIM
高出19.7%
-11.5%
净利率更高
FEIM
高出187.9%
-177.4%
自由现金流更多
FEIM
多$22.0M
$-23.1M
两年增速更快
FEIM
近两年复合增速
-12.2%
损益表 — Q2 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.1M | $19.6M |
| 净利润 | $1.8M | $-34.7M |
| 毛利率 | 38.2% | 48.5% |
| 营业利润率 | 10.0% | -168.5% |
| 净利率 | 10.5% | -177.4% |
| 营收同比 | 8.3% | -11.5% |
| 净利润同比 | -32.1% | -28.8% |
| 每股收益（稀释后） | $0.18 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FEIMLAB
| Q4 25 | $17.1M | — | ||
| Q3 25 | $13.8M | $19.6M | ||
| Q2 25 | $20.0M | $21.8M | ||
| Q1 25 | $18.9M | $40.8M | ||
| Q4 24 | $15.8M | — | ||
| Q3 24 | $15.1M | $22.1M | ||
| Q2 24 | $15.6M | $22.5M | ||
| Q1 24 | $13.7M | $45.5M |
净利润FEIMLAB
| Q4 25 | $1.8M | — | ||
| Q3 25 | $634.0K | $-34.7M | ||
| Q2 25 | $3.2M | $-33.5M | ||
| Q1 25 | $15.4M | $-26.0M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $2.4M | $-26.9M | ||
| Q2 24 | $2.6M | $-45.7M | ||
| Q1 24 | $130.0K | $-32.2M |
毛利率FEIMLAB
| Q4 25 | 38.2% | — | ||
| Q3 25 | 36.8% | 48.5% | ||
| Q2 25 | 37.5% | 48.8% | ||
| Q1 25 | 43.8% | 48.4% | ||
| Q4 24 | 48.2% | — | ||
| Q3 24 | 44.4% | 54.9% | ||
| Q2 24 | 40.3% | 46.1% | ||
| Q1 24 | 22.6% | 53.1% |
营业利润率FEIMLAB
| Q4 25 | 10.0% | — | ||
| Q3 25 | 2.6% | -168.5% | ||
| Q2 25 | 16.4% | -118.1% | ||
| Q1 25 | 18.3% | -80.8% | ||
| Q4 24 | 16.5% | — | ||
| Q3 24 | 15.7% | -120.9% | ||
| Q2 24 | 16.0% | -134.5% | ||
| Q1 24 | -3.4% | -132.2% |
净利率FEIMLAB
| Q4 25 | 10.5% | — | ||
| Q3 25 | 4.6% | -177.4% | ||
| Q2 25 | 16.0% | -153.7% | ||
| Q1 25 | 81.4% | -63.8% | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 16.1% | -122.0% | ||
| Q2 24 | 16.9% | -203.3% | ||
| Q1 24 | 0.9% | -70.6% |
每股收益（稀释后）FEIMLAB
| Q4 25 | $0.18 | — | ||
| Q3 25 | $0.07 | $-0.09 | ||
| Q2 25 | $0.33 | $-0.09 | ||
| Q1 25 | $1.60 | $-0.07 | ||
| Q4 24 | $0.28 | — | ||
| Q3 24 | $0.25 | $-0.07 | ||
| Q2 24 | $0.28 | $-0.12 | ||
| Q1 24 | $0.01 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $58.5M | $399.7M |
| 总资产 | $92.3M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FEIMLAB
| Q4 25 | $3.0M | — | ||
| Q3 25 | $4.5M | $129.4M | ||
| Q2 25 | $4.7M | $158.6M | ||
| Q1 25 | $5.5M | $150.9M | ||
| Q4 24 | $9.7M | — | ||
| Q3 24 | $16.2M | $210.6M | ||
| Q2 24 | $18.3M | $269.8M | ||
| Q1 24 | $11.7M | $287.1M |
总债务FEIMLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益FEIMLAB
| Q4 25 | $58.5M | — | ||
| Q3 25 | $56.3M | $399.7M | ||
| Q2 25 | $55.6M | $424.5M | ||
| Q1 25 | $51.8M | $454.6M | ||
| Q4 24 | $36.2M | — | ||
| Q3 24 | $33.2M | $489.3M | ||
| Q2 24 | $39.8M | $510.3M | ||
| Q1 24 | $36.7M | $577.3M |
总资产FEIMLAB
| Q4 25 | $92.3M | — | ||
| Q3 25 | $93.2M | $539.6M | ||
| Q2 25 | $93.7M | $557.0M | ||
| Q1 25 | $86.4M | $579.6M | ||
| Q4 24 | $77.8M | — | ||
| Q3 24 | $84.3M | $681.5M | ||
| Q2 24 | $83.3M | $708.7M | ||
| Q1 24 | $77.7M | $777.7M |
负债/权益比FEIMLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-523.0K | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.1M | $-23.1M |
| 自由现金流率自由现金流/营收 | -6.6% | -118.1% |
| 资本支出强度资本支出/营收 | 3.6% | 4.5% |
| 现金转化率经营现金流/净利润 | -0.29× | — |
| 过去12个月自由现金流最近4个季度 | $-5.5M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流FEIMLAB
| Q4 25 | $-523.0K | — | ||
| Q3 25 | $1.2M | $-22.2M | ||
| Q2 25 | $-155.0K | $-20.7M | ||
| Q1 25 | $-3.6M | $-30.3M | ||
| Q4 24 | $3.8M | — | ||
| Q3 24 | $-1.5M | $-27.9M | ||
| Q2 24 | $7.5M | $-39.0M | ||
| Q1 24 | $4.2M | $-62.5M |
自由现金流FEIMLAB
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $385.0K | $-23.1M | ||
| Q2 25 | $-786.0K | $-22.6M | ||
| Q1 25 | $-4.0M | $-35.3M | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $-1.8M | $-30.1M | ||
| Q2 24 | $6.7M | $-41.0M | ||
| Q1 24 | $3.9M | $-63.3M |
自由现金流率FEIMLAB
| Q4 25 | -6.6% | — | ||
| Q3 25 | 2.8% | -118.1% | ||
| Q2 25 | -3.9% | -103.6% | ||
| Q1 25 | -20.9% | -86.6% | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | -11.8% | -136.4% | ||
| Q2 24 | 42.8% | -182.2% | ||
| Q1 24 | 28.4% | -138.9% |
资本支出强度FEIMLAB
| Q4 25 | 3.6% | — | ||
| Q3 25 | 5.6% | 4.5% | ||
| Q2 25 | 3.2% | 8.7% | ||
| Q1 25 | 1.7% | 12.4% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.2% | 10.2% | ||
| Q2 24 | 5.3% | 8.6% | ||
| Q1 24 | 2.3% | 1.7% |
现金转化率FEIMLAB
| Q4 25 | -0.29× | — | ||
| Q3 25 | 1.83× | — | ||
| Q2 25 | -0.05× | — | ||
| Q1 25 | -0.24× | — | ||
| Q4 24 | 1.44× | — | ||
| Q3 24 | -0.60× | — | ||
| Q2 24 | 2.85× | — | ||
| Q1 24 | 32.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
